Nuveen Asset Management LLC Decreases Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Nuveen Asset Management LLC reduced its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 71.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 314,275 shares of the biotechnology company's stock after selling 792,421 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.21% of Heron Therapeutics worth $481,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Anfield Capital Management LLC grew its holdings in Heron Therapeutics by 5.6% in the fourth quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company's stock worth $182,000 after purchasing an additional 6,264 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Heron Therapeutics by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company's stock valued at $71,000 after buying an additional 8,684 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Heron Therapeutics by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock valued at $1,692,000 after buying an additional 9,418 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Heron Therapeutics by 10.6% in the fourth quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock worth $174,000 after acquiring an additional 10,909 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Heron Therapeutics by 22.2% during the fourth quarter. Wells Fargo & Company MN now owns 74,763 shares of the biotechnology company's stock worth $114,000 after acquiring an additional 13,568 shares during the last quarter. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Price Performance

NASDAQ HRTX traded up $0.02 during mid-day trading on Monday, hitting $2.12. The stock had a trading volume of 1,009,746 shares, compared to its average volume of 2,240,764. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.93. The firm's 50 day moving average is $2.02 and its 200 day moving average is $1.87. The stock has a market capitalization of $323.44 million, a price-to-earnings ratio of -11.78 and a beta of 1.15.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million for the quarter, compared to analyst estimates of $37.08 million. As a group, equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on HRTX. Needham & Company LLC restated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research note on Friday, April 11th. Wall Street Zen upgraded shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday. Finally, HC Wainwright initiated coverage on Heron Therapeutics in a research report on Monday. They set a "buy" rating and a $6.00 price target on the stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.